

Presentations

1. **Prof. Thomas Philipson** (Chicago Harris) - *Who Benefits from New Medical Technologies? Estimates for Consumer and Producer Surpluses for HIV/AIDS Drugs* (with Bapu Jena)
2. **Prof. Mark Duggan** (University of Maryland) - *The Short Run and Long-Run Impact of HIV Antiretroviral Treatments: Evidence from California's Medicaid Population*
3. **Prof. Sean Nicholson** (Cornell University) - *Does Financing Have A Real Effect on Biotech Drug Development?* (with Andrew Metrick and Patricia Danzon)
4. **Prof. Scott Stern** (Northwestern - Kellogg) - *Do Formal Intellectual Property Rights Hinder the Free Flow of Scientific Knowledge? An Empirical Test of the Anti-Commons Hypothesis* (with Fiona Murray)
5. **Prof. Ginger Jin** (University of Maryland) - *Patient Learning and Advertising in the Diffusion of Cox-2 Inhibitors*
6. **Prof. David Bradford** (Medical University of South Carolina) - *The Effect of Direct-to-Consumer Advertising on the Timing of Treatment* (with coauthors)

Panel Discussions

Incentives for New Drug Development:

1. **Dr. Joseph DiMasi** (Tufts Center for the Study of Drug Development)
2. **Dr. Randall Lutter** (FDA)
3. **Dr. Una Ryan** (AVANT Immunotherapeutics)
4. **Dr. Chris Adams** (FTC)
5. **Prof. David Ridley** (Duke)

Spillovers, Mergers and Pharmaceutical R&D:

1. **Dr. Peter Rankin** (Charles River Associates)
2. **Mr. Gerald Quirk** (Infinity Pharmaceuticals, Inc.)
3. **James Barrett** (NEA)
4. **Dr. Suzanne Majewski** (DOJ)
5. **Dr. Laura Hosken** (FTC)

Economics of Direct to Consumer Advertising:

1. **Dr. Jack Calfee** (AEI)
2. **Prof. Marta Wosinska** (HBS)

3. **Maureen Ohlhausen** (FTC)
4. **Dr. William Encinosa** (AHRQ)
5. **Dr. Richard Manning** (Pfizer)